Chas Bountra, SGC to Speak at Pain Therapeutics Meeting Sept 13-14 San Francisco

Monrovia, California (PressExposure) July 24, 2012 -- Chas Bountra, Chief Scientist at Structural Genomics Consortium will give a presentation on "Novel Epigenetic Targets for the Treatment of Pain" at the Pain Research and Therapeutics Conference taking place on Sept 13-14, 2012 in San Francisco, CA.

The biggest challenge in delivering novel treatments for pain is target selection and validation. To this end SGC has decided to focus its efforts on the following:

1. Epigenetic proteins because they potentially are superior targets
2. Working with big pharma to generate novel inhibitors and antibodies for these proteins
3. Using human disease cells for validation
4. Trying to establish a public private partnership to progress novel industry standard clinical candidates into clinical proof of concept studies, in the absence of I.P.

Chas is Chief Scientist at the Structural Genomics Consortium and Professor of Translational Medicine at the University of Oxford. His current research is aimed at determining the 3D X ray structures of novel proteins, generating novel small molecule inhibitors, using these to dissect disease networks and hence identifying new targets for drug discovery. The SGC publishes all findings immediately (> one per week), works closely with over 100 academic labs across the world and 6 pharmaceutical companies, and shares all reagents and expertise freely. Chas is an advocate for pre-competitive science, up to and including Phase IIa clinical studies. He has worked in the pharmaceutical industry, and has experience of all stages of target and candidate discovery, Phase 1, II and III clinical studies. His therapeutic expertise is in neuro-psychiatric, gastro-intestinal (GI) and inflammatory diseases.

GTC's Pain Research and Therapeutics will discuss the latest breakthroughs, new drug targets, therapeutic approaches, preclinical and clinical development, and animal models, beyond traditional opioids, overcoming challenges in pain therapeutics, and much more. The conference is also a part of the 2nd CNS Diseases World Summit. The Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partnering and deal-making.

Join your colleagues at this exciting Pain Therapeutics conference and CNS summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Stephen Brannan - VP at Takeda, Tony L. Yaksh at UCSD, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, David Shelton at Pfizer, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, Michael C. Venuti - CSO at NeuroTherapeutics, and many more!

For more information, please visit

About GTC Conferences

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: July 24, 2012 at 1:20 am
This article has been viewed 58249 time(s).